ElectroCore, Inc. 10-Q Summary
Business Context and Reporting Period
ElectroCore is a commercial-stage bioelectronic medicine and wellness company developing and selling non-invasive vagus nerve stimulation products, including prescription gammaCore, consumer wellness product Truvaga, and human-performance product TAC-STIM. This filing covers the three and nine months ended September 30, 2023, filed November 8, 2023. The company is a smaller reporting company and emerging growth company.
Financial Results and Key Metrics
| Metric | Q3 2023 | Q3 2022 | Nine Months 2023 | Nine Months 2022 |
|---|---|---|---|---|
| Net sales | $4.508 million | $1.976 million | $10.839 million | $6.032 million |
| Gross profit | $3.847 million | $1.718 million | $9.135 million | $5.056 million |
| Gross margin | 85% | 87% | 84% | 84% |
| Loss from operations | $(4.126) million | $(5.556) million | $(15.311) million | $(16.957) million |
| Net loss | $(4.032) million | $(5.453) million | $(14.802) million | $(16.372) million |
| Basic and diluted loss per share | $(0.68) | $(1.20) | $(2.87) | $(3.45) |
| Cash used in operating activities | Not provided for quarter | Not provided for quarter | $(11.545) million | $(12.631) million |
At September 30, 2023, cash and cash equivalents were $13.460 million, restricted cash was $0.250 million, and total assets were $20.108 million. Current assets were $17.839 million versus current liabilities of $8.508 million. Total liabilities were $9.068 million, consisting primarily of operating liabilities and lease obligations; the filing does not report conventional long-term debt. A $0.618 million insurance-premium financing arrangement remained outstanding at approximately $0.433 million at quarter-end.
Cash, cash equivalents, and restricted cash decreased to $13.710 million at September 30, 2023 from $17.962 million at December 31, 2022. Financing activities provided $7.487 million, primarily from the July 2023 equity financing, while investing activities used $0.165 million for equipment.
Material Changes Versus Prior Comparable Period
- Q3 revenue increased 128% to $4.508 million; nine-month revenue increased 80% to $10.839 million.
- Growth reflected higher VA/DoD gammaCore sales and new Truvaga and TAC-STIM revenue. Q3 Truvaga revenue was $0.267 million and TAC-STIM revenue was $0.601 million; nine-month amounts were $0.704 million and $1.000 million, respectively.
- VA/DoD represented 60.7% of Q3 revenue and 60.2% of nine-month revenue, creating significant customer concentration.
- Q3 gross margin declined to 85% from 87%, while nine-month gross margin remained 84%.
- Q3 operating loss improved by $1.430 million, and nine-month operating loss improved by $1.646 million, despite higher selling, general and administrative expenses.
- Q3 research and development expense decreased $0.368 million, while selling, general and administrative expense increased $1.067 million. Nine-month SG&A included $0.445 million of severance charges and increased variable selling and marketing costs.
- The company raised approximately $7.5 million net in July through common stock, pre-funded warrants, and warrants. The financing increased common shares outstanding and created potential future dilution.
- The company completed a 1-for-15 reverse stock split effective February 15, 2023, and eliminated its Series A preferred stock.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing provides no formal revenue or earnings guidance. Management expects continued negative operating cash flow and continued targeted investment in sales and marketing and the next generation of its therapy delivery platform. Management expects cash and anticipated revenue to fund currently planned operations for 12 months from the financial statement date, but the company states that substantial doubt exists about its ability to continue as a going concern within one year.
- The VA/DoD Federal Supply Schedule contract, which supports a majority of expected 2023 sales, was scheduled to expire January 15, 2024. The company submitted a renewal application, but renewal and favorable terms are not assured.
- The company reported that NHS Supply Chain intended to continue including gammaCore in a framework agreement beginning March 2024 through March 2026, subject to the stated conditions. NICE guidance or pricing changes could adversely affect the U.K. opportunity.
- Management identified a material weakness in internal control over financial reporting relating to vendor payment security after an unauthorized payment based on incorrect vendor information. No financial statement misstatement was identified. Disclosure controls were therefore ineffective as of September 30, 2023, and remediation was underway.
- Stockholder litigation remains subject to an appeal in the Turnofsky matter. The company has not accrued a loss because it cannot determine the probability or range of potential loss; unfavorable outcomes could result in substantial defense costs, judgments, or settlements.
- Revenue depends heavily on government and health-system channels, product acceptance, reimbursement, regulatory requirements, sales execution, and the commercial performance of relatively new products.
- Inventory included a $0.258 million reserve charge during the nine months. Inventory reserves totaled approximately $0.5 million at September 30, 2023.
Important Facts for Investors to Verify
- Whether the VA/DoD Federal Supply Schedule was renewed after its January 2024 expiration and on what terms.
- Cash burn, available liquidity, and any additional equity or other financing required to fund operations.
- Progress and operating effectiveness of remediation for the vendor-payment control material weakness.
- Sustainability and quality of revenue growth, particularly the contribution and margins of TAC-STIM and Truvaga.
- Customer concentration, including the continuing percentage of revenue generated by VA/DoD.
- Status and potential financial exposure of the Turnofsky appeal and related stockholder litigation.
- Potential dilution from approximately 0.924 million outstanding stock purchase warrants, 0.613 million pre-funded warrants, stock options, and restricted stock units.